SCHEMBL6732463

SCHEMBL6732463

FC(F)(F)Oc1cccc(NCc2cccnc2)c1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 8/20 0.62
CYP3A4 P08684 7/20 0.62
CYP2C9 P11712 7/20 0.62
CYP2D6 P10635 5/20 0.62
CYP1A2 P05177 5/20 0.62
LTA4H P09960 1/20 0.56
MEN1 O00255 1/20 0.56
MAPT P10636 1/20 0.56
PABPC1 P11940 1/20 0.56
KMT2A Q03164 1/20 0.56
KDM5A P29375 1/20 0.54
KDM4C Q9H3R0 1/20 0.54
KDM5B Q9UGL1 1/20 0.54
NAMPT P43490 1/20 0.53
GRM2 Q14416 2/20 0.50
SGMS2 Q8NHU3 1/20 0.50
ALDH1A1 P00352 1/20 0.49
F2 P00734 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5265011 0.86 CYP3A4 (0.48) CYP2C19CYP3A4CYP2C9CYP2D6CYP1A2
SCHEMBL19312422 0.82 LTA4H (0.60) CYP2C19CYP3A4CYP2C9CYP2D6CYP1A2
SCHEMBL10558040 0.80 KIF11 (0.62) CYP2C19CYP3A4CYP2C9CYP2D6CYP1A2
SCHEMBL6727909 0.79 MAPK1 (0.70) LTA4HMEN1MAPTPABPC1KMT2A
SCHEMBL6733124 0.79 MAPT (0.59) CYP2C19CYP3A4CYP2C9CYP2D6CYP1A2
SCHEMBL13766316 0.77 LTA4H (0.66) CYP2D6CYP1A2LTA4HMEN1MAPT
SCHEMBL3282376 0.77 MAPK14 (0.59) KDM5AKDM4CKDM5B
SCHEMBL19967202 0.77 LMNA (0.43) CYP2C19CYP3A4CYP2C9CYP2D6CYP1A2
SCHEMBL6732917 0.76 LTA4H (0.56) CYP2C19CYP3A4CYP2C9CYP2D6CYP1A2
SCHEMBL6731979 0.76 LTA4H (0.56) CYP2C19CYP3A4CYP2D6CYP1A2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US disclosed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US disclosed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP disclosed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 CYP2C19 2053/4885CYP3A4 2786/4885CYP2C9 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.